Vascular Technologies Inc. Announces the Presentation of its Proprietary Ultroid Hemorrhoid Treatment Program to More Than 500 Physicians in Barcelona, Spain, September 24-26, 2014

    TAMPA, FL, December 18, 2014 /24-7PressRelease/ -- Vascular Technologies Inc. and its wholly owned subsidiaries (the "Company"), today announced that more than 500 physicians and professionals had seen the Ultroid UK presentation at the 9th Annual Meeting of the European Association of Coloproctology, held in Barcelona, Spain, from September 24 to September 26, 2014.

More than 1,000 professionals attended the meeting, and Ultroid UK had a booth at the show, where additional information was available, and where meetings with foreign groups were held.

Dr. Mark Hudson-Peacock, M.D., the European Medical Director for Ultroid , presented a paper on his experience with the first 100 patients in the UK who received Ultroid treatment. He highlighted the safety and minimal discomfort that was previously reported by other Ultroid researchers. The congress hall was packed during the meeting.

Dr. Hudson-Peacock also noted that some patients had anal fissures as well as hemorrhoids, and these fissures cleared up following the Ultroid treatment. Dr. Hudson-Peacock's second paper discussed these findings and highlighted the need for further research.

With this in mind, he requested that other surge`ons discovering similar findings contact him to continue these discussions and research. Dr. Hudson-Peacock and Ultroid UK are committed to an ongoing program of research and are looking forward to presenting additional research and results at 2015 conferences.

In commenting on the conference, Mr. Michael Cao, the Company's Founder and Chairman, stated that "Dr. Hudson-Peacock's experience with these 100 patients is a prime example of the powerful appeal of the Ultroid system, and its potential value to physicians and health care systems around the world."

ABOUT VASCULAR TECHNOLOGIES INC. AND ULTROID
Vascular Technologies Inc., a Nevada corporation and its several wholly owned Florida Ultroid subsidiaries, have developed, patented, and obtained FDA and international clearance for the Ultroid system and procedure, providing a permanent solution for symptomatic hemorrhoids, utilizing a disposable, single use element combined with a painless milliamp and minimal voltage direct current. The procedure, which has been utilized more than 120,000 times for the treatment and resolution of symptomatic hemorrhoids, is safe, non-surgical, requires no anesthetic, minimizes the pain of the hemorrhoid and its treatment, requires no recuperation time, can be utilized for all four grades of internal and mixed hemorrhoids, and is reimbursable by all major insurance organization as well as Medicare and Worker Compensation programs. The Ultroid procedure is the exclusive treatment of various hemorrhoid clinics within the United States, the UK (including a Harley Street clinic in London), and additional clinics are planned for the Americas, Europe, the Middle East, and Asia. The Ultroid procedure can be utilized by family practice physicians and internists, OB/GYNs, gastroenterologists, clinics, surgical centers, hospitals, and others.

Forward Looking Statements:
Statements in this press release that are not purely historical facts, including statements regarding the Company's beliefs, expectations, intentions or strategies for the future, may be "forward-looking statements" under the Private Securities Litigation Reform Act of 1996. Such statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as "plan," "may," "expect," "anticipate," "intend," "estimate," or "continue," or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward-looking statements are speculative, and there are certain risks and uncertainties that could cause actual events or results to differ from those referred to in such forward-looking statements. This disclosure highlights some of the important risks regarding our business. Specifically, the reader should not place undue reliance on statements regarding our ability to develop future activities, or to make successful strategic decisions and investments.

Ultroid maintains an informational website at: www.ultroid.com, and its UK strategic partner's website is at: www.ultroiduk.com.

The Company's Investment Banking Consultant is Dawson James Securities, Member: FINRA/SIPC, 1 South Federal Highway, Boca Raton, Fl 33432, attention: Mr. Carlo Corzine, +1.561.391.5555

For further information and investor relations contact:

Mark Kallan, President
Vascular Technologies Inc.
3140 W. Kennedy Boulevard
Tampa, Fl 33609
Telephone: +1.727.898.0717 ext. 3

# # #